HAS reimburses iptacopan for second-line use only, in patients who have already had at least six months of anti-C5 therapy — a materially narrower population than the US or UK approvals cover.
France's Commission de la Transparence issued a favourable reimbursement opinion for iptacopan (Fabhalta) only in adults with symptomatic haemolytic anaemia after at least six months on a C5 complement inhibitor, and an unfavourable opinion for the other situations its marketing authorisation covers. That restriction is one the FDA and MHRA labels do not carry. Ravulizumab (Ultomiris) holds the opposite position: a favourable opinion with first-line positioning, which HAS grounded in its every-eight-week dosing advantage over eculizumab's every-two-week schedule rather than in any demonstrated efficacy or tolerance benefit. The comparator relationship is asymmetric: ravulizumab defends first place, and iptacopan has to earn its way in from second line.
That asymmetry sets up the CEPS price negotiation differently for each drug, and it does so before price is discussed at all. A second-line-only indication removes every treatment-naive patient from iptacopan's addressable population, while ravulizumab's first-line position never had to argue past a prior-treatment gate. A commercial plan built on the US or UK label alone would miss this entirely. The specific ASMR level granted and the negotiated CEPS prices for both agents could not be established in the public record available to us, and are deliberately omitted rather than estimated.
France PNH treatment landscape — HAS reimbursement position by agent
| Agent | HAS position | Eligibility gate | Basis cited |
|---|---|---|---|
| Ultomiris (ravulizumab) | First-line | None within the reimbursed indication | Every-eight-week dosing vs eculizumab's every-two-week schedule |
| Fabhalta (iptacopan) | Second-line only | Symptomatic haemolytic anaemia after ≥6 months on a C5 inhibitor | Favourable opinion for that population only; unfavourable for other situations in the marketing authorisation |
Sources: HAS Commission de la Transparence, FABHALTA (iptacopan) — hémoglobinurie paroxystique nocturne; HAS Commission de la Transparence, ULTOMIRIS (ravulizumab); HAS, Avis économique FABHALTA (iptacopan), 5 décembre 2024.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The Commission de la Transparence's exact eligibility language and the situations it declined to reimburse
- how this compares to the broader US and UK positioning
Delivers
- The prior-treatment gate and the patients it removes
- how a restricted indication changes CEPS negotiation leverage for a specialty oral therapy
Delivers
- Ravulizumab's first-line status and the q8w vs q2w dosing rationale HAS cited
- the asymmetric comparator relationship this creates
Custom brief delivered in 72 hours.
Assess this reportWhat's inside
- What French epidemiology data exists for PNH, and how it compares to UK/German extrapolation practice
- Diagnostic pathway through French reference centres
- How SMR sets reimbursement eligibility and ASMR anchors CEPS price negotiation
- Where iptacopan and ravulizumab sit under each
- Eculizumab, ravulizumab, and iptacopan positioning under the French framework
- The ≥6-month prior anti-C5 criterion and the situations HAS declined to reimburse
- How this narrows the addressable population versus the US/UK label
- How CEPS anchors price to the ASMR rating, target population and European reference prices
- What a restricted indication does to negotiation leverage
- French PNH reference centre network
- Prescribing posture under the first-line/second-line split
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (HAS, EMA, ANSM), not secondary summaries. Findings are independently verified before inclusion.
PNH France CI sources: HAS Commission de la Transparence records for iptacopan and ravulizumab, and HAS's economic opinion on iptacopan of 5 December 2024. Figures that could not be traced to a primary source — the ASMR level granted and the negotiated CEPS prices — are omitted rather than estimated.
- Iptacopan's second-line-only reimbursement opinion and its ≥6-month prior anti-C5 criterion verified against the live HAS Commission de la Transparence record
- Ravulizumab's first-line positioning and the dosing rationale verified against HAS Commission de la Transparence documentation
- The ASMR level granted and the negotiated CEPS prices could not be established in the public record, and are omitted rather than estimated
Frequently asked questions
Commission this brief
AXLRx PNH Disease Landscape is built for commercial, medical affairs, and market access teams that need a rigorous, evidence-based characterisation of the French PNH patient population and the HAS/CEPS access pathway. Custom brief in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.